Publication

Autoantibodies to high mobility group box 1 in patients with Incomplete and Systemic Lupus Erythematosus

Schaper, F., De Leeuw, K., Horst, G., Maas, F., Beijeren, D. V., Bijzet, J., Heeringa, P., Limburg, P. C. & Westra, J., 1-Jan-2015, p. 15. 1 p.

Research output: Contribution to conferenceAbstractAcademic

APA

Schaper, F., De Leeuw, K., Horst, G., Maas, F., Beijeren, D. V., Bijzet, J., ... Westra, J. (2015). Autoantibodies to high mobility group box 1 in patients with Incomplete and Systemic Lupus Erythematosus. 15. Abstract from 11th International Congress on Systemic Lupus Erythematosus, .

Author

Schaper, F. ; De Leeuw, K. ; Horst, G. ; Maas, F. ; Beijeren, D.V. ; Bijzet, J. ; Heeringa, P. ; Limburg, P.C. ; Westra, J. / Autoantibodies to high mobility group box 1 in patients with Incomplete and Systemic Lupus Erythematosus. Abstract from 11th International Congress on Systemic Lupus Erythematosus, .1 p.

Harvard

Schaper, F, De Leeuw, K, Horst, G, Maas, F, Beijeren, DV, Bijzet, J, Heeringa, P, Limburg, PC & Westra, J 2015, 'Autoantibodies to high mobility group box 1 in patients with Incomplete and Systemic Lupus Erythematosus' 11th International Congress on Systemic Lupus Erythematosus, 02/09/2015 - 06/09/2015, pp. 15.

Standard

Autoantibodies to high mobility group box 1 in patients with Incomplete and Systemic Lupus Erythematosus. / Schaper, F.; De Leeuw, K.; Horst, G.; Maas, F.; Beijeren, D.V.; Bijzet, J.; Heeringa, P.; Limburg, P.C.; Westra, J.

2015. 15 Abstract from 11th International Congress on Systemic Lupus Erythematosus, .

Research output: Contribution to conferenceAbstractAcademic

Vancouver

Schaper F, De Leeuw K, Horst G, Maas F, Beijeren DV, Bijzet J et al. Autoantibodies to high mobility group box 1 in patients with Incomplete and Systemic Lupus Erythematosus. 2015. Abstract from 11th International Congress on Systemic Lupus Erythematosus, .


BibTeX

@conference{3677b454b1324461b197b5dbdd8256ee,
title = "Autoantibodies to high mobility group box 1 in patients with Incomplete and Systemic Lupus Erythematosus",
abstract = "Introduction. High Mobility Group Box-1 (HMGB1) is involved in the pathogenesis of Systemic Lupus Erythematosus (SLE). However, the role of autoantibodies to HMGB1 is unclear. Therefore levels of anti-HMGB1 and their reactivity to HMGB1 BoxA and BoxB were examined in association with disease activity and clinical parameters. Methods. Eighty-six SLE patients, 34 patients with incomplete lupus (ILE) and 44 age- and sex-matched healthy controls (HC) were included. Anti-HMGB1 levels were measured during quiescent disease (SLEDAI ≤4, n=47), and active disease (SLEDAI ≥5 n=39). Serum IgG, IgM anti-HMGB1 levels and reactivity against Box A and B were measured using ELISA. Results. Quiescent and active SLE patients had significantly increased anti- HMGB1 IgG levels compared to HC. There was no difference in anti-HMGB1 levels between active and quiescent patients. ILE patients did not have increased anti-HMGB1 levels. Anti-HMGB1 IgM in HC, ILE, quiescent and active SLE patients were comparable. There were no associations between anti-HMGB1 and disease activity, anti-ds DNA. However, patients with arthritis had higher anti- HMGB1 levels, while patients with neurological involvement had lower levels. Anti-HMGB1 levels were similar in active disease and subsequent remission. Patients with antibodies directed against both Box A and B had higher SLEDAI, increased anti-ds DNA, lower complement C3 levels, and higher total anti-HMGB1. Conclusion. Although anti-HMGB1 IgG levels are increased in SLE patients, no clear relation with disease activity or specific clinical symptoms was found. Therefore, anti-HMGB1 levels do not seem to be a useful biomarker of active disease or organ involvement.",
keywords = "autoantibody, immunoglobulin G, double stranded DNA, immunoglobulin M, antibody, biological marker, DNA, systemic lupus erythematosus, patient, human, disease activity, serum, parameters, remission, arthritis, pathogenesis, SLEDAI, enzyme linked immunosorbent assay",
author = "F. Schaper and {De Leeuw}, K. and G. Horst and F. Maas and D.V. Beijeren and J. Bijzet and P. Heeringa and P.C. Limburg and J. Westra",
year = "2015",
month = "1",
day = "1",
language = "English",
pages = "15",
note = "11th International Congress on Systemic Lupus Erythematosus ; Conference date: 02-09-2015 Through 06-09-2015",

}

RIS

TY - CONF

T1 - Autoantibodies to high mobility group box 1 in patients with Incomplete and Systemic Lupus Erythematosus

AU - Schaper, F.

AU - De Leeuw, K.

AU - Horst, G.

AU - Maas, F.

AU - Beijeren, D.V.

AU - Bijzet, J.

AU - Heeringa, P.

AU - Limburg, P.C.

AU - Westra, J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction. High Mobility Group Box-1 (HMGB1) is involved in the pathogenesis of Systemic Lupus Erythematosus (SLE). However, the role of autoantibodies to HMGB1 is unclear. Therefore levels of anti-HMGB1 and their reactivity to HMGB1 BoxA and BoxB were examined in association with disease activity and clinical parameters. Methods. Eighty-six SLE patients, 34 patients with incomplete lupus (ILE) and 44 age- and sex-matched healthy controls (HC) were included. Anti-HMGB1 levels were measured during quiescent disease (SLEDAI ≤4, n=47), and active disease (SLEDAI ≥5 n=39). Serum IgG, IgM anti-HMGB1 levels and reactivity against Box A and B were measured using ELISA. Results. Quiescent and active SLE patients had significantly increased anti- HMGB1 IgG levels compared to HC. There was no difference in anti-HMGB1 levels between active and quiescent patients. ILE patients did not have increased anti-HMGB1 levels. Anti-HMGB1 IgM in HC, ILE, quiescent and active SLE patients were comparable. There were no associations between anti-HMGB1 and disease activity, anti-ds DNA. However, patients with arthritis had higher anti- HMGB1 levels, while patients with neurological involvement had lower levels. Anti-HMGB1 levels were similar in active disease and subsequent remission. Patients with antibodies directed against both Box A and B had higher SLEDAI, increased anti-ds DNA, lower complement C3 levels, and higher total anti-HMGB1. Conclusion. Although anti-HMGB1 IgG levels are increased in SLE patients, no clear relation with disease activity or specific clinical symptoms was found. Therefore, anti-HMGB1 levels do not seem to be a useful biomarker of active disease or organ involvement.

AB - Introduction. High Mobility Group Box-1 (HMGB1) is involved in the pathogenesis of Systemic Lupus Erythematosus (SLE). However, the role of autoantibodies to HMGB1 is unclear. Therefore levels of anti-HMGB1 and their reactivity to HMGB1 BoxA and BoxB were examined in association with disease activity and clinical parameters. Methods. Eighty-six SLE patients, 34 patients with incomplete lupus (ILE) and 44 age- and sex-matched healthy controls (HC) were included. Anti-HMGB1 levels were measured during quiescent disease (SLEDAI ≤4, n=47), and active disease (SLEDAI ≥5 n=39). Serum IgG, IgM anti-HMGB1 levels and reactivity against Box A and B were measured using ELISA. Results. Quiescent and active SLE patients had significantly increased anti- HMGB1 IgG levels compared to HC. There was no difference in anti-HMGB1 levels between active and quiescent patients. ILE patients did not have increased anti-HMGB1 levels. Anti-HMGB1 IgM in HC, ILE, quiescent and active SLE patients were comparable. There were no associations between anti-HMGB1 and disease activity, anti-ds DNA. However, patients with arthritis had higher anti- HMGB1 levels, while patients with neurological involvement had lower levels. Anti-HMGB1 levels were similar in active disease and subsequent remission. Patients with antibodies directed against both Box A and B had higher SLEDAI, increased anti-ds DNA, lower complement C3 levels, and higher total anti-HMGB1. Conclusion. Although anti-HMGB1 IgG levels are increased in SLE patients, no clear relation with disease activity or specific clinical symptoms was found. Therefore, anti-HMGB1 levels do not seem to be a useful biomarker of active disease or organ involvement.

KW - autoantibody

KW - immunoglobulin G

KW - double stranded DNA

KW - immunoglobulin M

KW - antibody

KW - biological marker

KW - DNA

KW - systemic lupus erythematosus

KW - patient

KW - human

KW - disease activity

KW - serum

KW - parameters

KW - remission

KW - arthritis

KW - pathogenesis

KW - SLEDAI

KW - enzyme linked immunosorbent assay

UR - http://www.embase.com/search/results?subaction=viewrecord&rid=1&page=1&id=L71976696

M3 - Abstract

SP - 15

ER -

ID: 30150441